Relatlimab (BMS-986016) is a human monoclonal antibodyanti-LAG-3antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinantLAG-3protein. Relatlimab blocks LAG-3/MHC II interaction with anIC₅₀value of 0.67 nM and LAG-3/FGL1 interaction with anIC₅₀value of 0.019 nM. Relatlimab can be used in research ofcancer^[1].

Relatlimab (BMS-986016; 0.001-100 nM) recognizes native LAG-3 and binds to primary activated human and cynomolgus CD4+ T cells with EC₅₀values of 0.11 nM and 29.11 nM, respectively^[1].
Relatlimab (0.001-10000 nM; T cells (3A9-hLAG-3)) enhances peptide responsiveness of T-cell hybridoma 3A9-hLAG-3 and reversals LAG-3-mediated inhibition of T-cell hybridoma 3A9-hLAG-3 with an IC₅₀value of 1.05 nM^[1].
Relatlimab (0.001-10000 nM; primary T cells) enhances activation of superantigen-stimulated human PBMC cultures and enhances IL-2 secretion^[1].

Liquid

1673516-98-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.